uploads///ousa chea  unsplash

What Are Analysts Recommending for PFE and AZN?

By

Updated

Stock price movements

On April 11, Pfizer (PFE) closed at $42.27, 1.08% lower than its previous closing price, 22.99% higher than its 52-week low of $34.37, and 9.04% below its 52-week high of $46.47. The company’s market cap is $244.79 billion, and its PE, forward PE, PS (price-to-sales), and PB (price-to-book) ratios are 24.59x, 13.81x, 4.56x, and 3.86x, respectively.

Since its fourth-quarter earnings release on January 29, Pfizer stock has risen 4.58% from $40.42 on January 29 to $42.27 on April 11.

Article continues below advertisement

On April 11, AstraZeneca (AZN) closed at $39.84, 1.73% lower than its previous closing price, 15.88% higher than its 52-week low of $34.38, and 7.98% lower than its 52-week high of $43.29. The company’s market cap is $103.37 billion, and its PE, forward PE, PS, and PB ratios are 46.87x, 19.01x, 4.68x, and 8.10x, respectively.

Since its fourth-quarter earnings release on February 14, AstraZeneca’s share price has risen 1.94% from $39.08 on February 14 to $39.84 on April 11.

Analysts’ recommendations and target prices

Wall Street analysts expect a potential upside of 4.94% for Pfizer based on the company’s closing price on April 11. Analysts reduced the company’s 12-month consensus target price from $44.46 in February to $44.14 in March but raised it to $44.36 in April. The current consensus analyst recommendation on the stock is a “hold.”

Of the 15 analysts covering Pfizer, two have given the company “strong buy” ratings, five have given it “buy” ratings, seven have given it “holds,” and only one has given it a “strong sell.”

Wall Street analysts expect a potential upside of 15.71% for AstraZeneca based on the company’s closing price on April 11. Analysts raised the company’s 12-month consensus target price first from $42.06 in February to $45.77 in March and then to $46.10 in April. The current consensus analyst recommendation on the stock is a “buy.”

Of the five analysts covering AstraZeneca, three have rated the company as a “strong buy,” one has rated it as a “buy,” and the remaining one has rated it as a “hold.”

Advertisement

More From Market Realist